GlassScriptPhysician profile
Jaime L Baquero
NPI 1497779474
$4,452.92
in general payments reported to CMS, 2019-2025
28 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $164 · 2021: $215 · 2022: $448 · 2023: $647 · 2024: $1,293 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,231.04 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $597.48 | 2019-2024 | Qelbree, Qelbree |
| Eisai INC. | $435.78 | 2019-2020 | |
| Neurelis, INC. | $385.56 | 2022-2024 | Valtoco |
| Corium, LLC | $241.37 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $209.80 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $186.36 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $144.64 | 2023-2024 | |
| Livanova USA, INC. | $142.31 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Sunovion Pharmaceuticals INC. | $137.65 | 2019-2020 | |
| Biogen, INC. | $117.05 | 2019-2022 | |
| Genentech USA, INC. | $87.53 | 2019-2024 | Evrysdi |
| Neos Therapeutics, LP | $73.75 | 2019-2020 | |
| Janssen Biotech, INC. | $67.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.27 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.81 | 2019 | |
| Tris Pharma INC | $48.13 | 2019 | |
| Sumitomo Pharma America, INC. | $40.41 | 2023 | Aptiom |
| Pfizer INC. | $30.58 | 2024 | |
| Ceribell, INC. | $30.00 | 2024 | Pocket Eeg Device |
| Insulet Corporation | $29.89 | 2024 | Omnipod |
| Adlon Therapeutics L.P. | $22.16 | 2020 | |
| Shire North American Group INC | $19.84 | 2019 | |
| Acadia Pharmaceuticals INC | $17.66 | 2025 | Daybue |
| Eton Pharmaceuticals, INC. | $17.09 | 2023 | Alkindi |
| Collegium Pharmaceutical, INC. | $13.76 | 2025 | Jornay Pm |
| Medtronic, INC. | $13.43 | 2023 | Inpen Smart Insulin Delivery System |
| Travere Therapeutics, INC. | $5.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Baquero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.